Among 5-HT3A antagonists, those that can cross the BBB are suitable for treating neurological diseases such as memory and cognitive impairment, through their interaction mechanism in the CNS, while agents that cannot pass BBB are suitable for treating IBS, nausea, and vomiting [23]. The gene discussed is HTR3A; the disease is nervous system disorder.